Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial

Abstract

The Netherlands Trial Register #NTR166 (www.trialregister.nl) and the International Standard Randomised Controlled Trial, #ISRCTN95796863 (http://isrctn.org).

Pluripotent Stem Cell-Engineered Cell Sheets Reassembled with Defined Cardiovascular Populations Ameliorate Reduction in Infarct Heart Function Through Cardiomyocyte-Mediated Neovascularization

“…With discoveries of various stem/progenitor cell populations possessing cardiogenic or cardioprotective potential, the notion of restorative stem cell therapies has begun to take shape [1][2][3][4][5][6][7][8]. Several clinical trials and preclinical reports have demonstrated that intracoronary or intramyocardial injection of bone marrow (BM)-derived cells (hematopoietic stem/progenitor cells, mesenchymal stem cells, and endothelial progenitor cells) [9][10][11][12][13][14], skeletal myoblasts [15,16], or cardiac stem/ progenitor cells [17,18] ameliorate cardiac function following acute and chronic myocardial infarction (MI), even though there is still a deficiency in conclusive results for a full-scale therapy [19][20][21]. There seems to be little differentiation of transplanted stem cells into mature cardiovascular cell types, suggesting paracrine effects of transplanted cells in which humoral factors favorably affect the injured myocardium, including angiogenesis, apoptosis prevention, and promotion of healing [18,[22][23][24][25][26][27].…”

Ex-Vivo Expansion of Cardiac Stem Cell Therapy Products for Clinical Use: The Importance of Moving towards the Optimization of Process Development

“…The BOOST and the FINCELL trials further confirmed the significant improvement in LVEF by angiography in the stem cell treated groups [3,4]. By contrast, the latest HEBE trial completed in 2011, the Swiss-AMI trial and the ASTAMI trial reported similar or reduced effect of BMMNC therapy and the placebo [5][6][7]. Of note, in the HEBE trial, cells were processed for an undefined period of time and were delivered to patients in a heparin solution containing human serum albumin.…”

Cardiac Repair Using Stem Cells Conditioned Media Based Therapy in a Rodent Model of Myocardial Infarction and Heart Failure

“…human and animal models, to varying degrees of success [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] . In animal models, these cellbased therapies have demonstrated effectiveness in reducing infarct size and ventricular dilatation, and improving myocardial function [24][25][26] .…”